Panbela Therapeutics, Inc. Common Stock
PBLA
PBLA was delisted on the 6th of March, 2024.
7 hedge funds and large institutions have $2.74M invested in Panbela Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, 1 reducing their positions, and 4 closing their positions.
133% more capital invested
Capital invested by funds: $1.17M → $2.74M (+$1.57M)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
17% more funds holding
Funds holding: 6 → 7 (+1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.58M |
| 2 |
FPS
Fieldpoint Private Securities
Greenwich,
Connecticut
|
+$901K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$225K |
| 4 |
Squarepoint
New York
|
+$113K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$320K |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$225K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$225K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$78K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$62K |
PBLA Hedge Fund Activity: Q1 2021 in Review
7 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Panbela Therapeutics, Inc. Common Stock (PBLA) for Q1 2021, worth a combined $2.74M — up 133% from $1.17M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PBLA positions and 4 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.58M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $320K sold.
- 7 institutional investors held Panbela Therapeutics, Inc. Common Stock (PBLA) as of Q1 2021, up from 6 in Q4 2020.
- Funds reported $2.74M of Panbela Therapeutics, Inc. Common Stock stock for Q1 2021, up 133% quarter-over-quarter.
- 5 funds opened new Panbela Therapeutics, Inc. Common Stock positions in Q1 2021 and 4 closed out, a net change of +1 holder.
- The largest Panbela Therapeutics, Inc. Common Stock buyer in Q1 2021 was Ikarian Capital, an estimated $1.58M added.
- The largest Panbela Therapeutics, Inc. Common Stock seller in Q1 2021 was AIGH Capital Management, an estimated $320K sold.
Based on aggregated 13F filings for Q1 2021.